Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Respiratory Viruses in Bronchiolitis and Their Link to Recurrent Wheezing and Asthma

Jonathan M. Mansbach, MDa,*, Carlos A. Camargo, Jr, MD, DrPHb

One of the earliest and most common infectious respiratory conditions of childhood is bronchiolitis.1,2 A child who has severe bronchiolitis (e.g., an episode requiring hospitalization) is at increased risk for recurrent wheezing of childhood and eventual asthma.3–5 Estimates vary but approximately 80% to 90% of asthma begins before age 6 years, with 70% of children who have asthma having asthmalike symptoms before age 3 years.6,7 Although many environmental and genetic factors may play a role in the pathway from bronchiolitis to asthma,3,8 this article focuses on the viruses that have been linked to bronchiolitis and how these viruses may predict or contribute to future wheezing and asthma. The article also discusses vitamin D as an emerging risk factor for respiratory infections and wheezing.

DEFINITIONS OF LOWER RESPIRATORY TRACT INFECTION

In the United States, lower respiratory tract infections (LRTI) represent almost 60% of infant infectious disease hospitalizations9 and bronchiolitis is the most common LRTI.10 Despite its high frequency, bronchiolitis remains a clinical diagnosis11–13 without a common international definition.10,14–18 In 2006, the American Academy of Pediatrics defined bronchiolitis as a child younger than 2 years of age who has...
"rhinitis, tachypnea, wheezing, cough, crackles, use of accessory muscles, and/or nasal flaring."\(^{10}\) This definition is broad, and when children younger than 2 years of age present to care with symptoms suggestive of an LRTI, they receive various diagnostic labels, such as bronchiolitis, wheezing, cough, reactive airways disease, asthma, or pneumonia.\(^{19}\)

As our understanding of LRTI evolves and we identify more clearly the risk factors for children developing recurrent wheezing in preschool years (and asthma as they grow older), we may need to adjust our LRTI definitions. Indeed, based on 259 wheezing hospitalized children aged 3 to 35 months participating in a systemic corticosteroid and wheezing study in Finland, Jartti and colleagues\(^ {18}\) recently suggested that the diagnosis of bronchiolitis should be restricted either to children younger than 24 months of age who have their first episode of wheezing or to children younger than 12 months of age.

**BRONCHIOLITIS EPIDEMIOLOGY**

With its broad definition, bronchiolitis is the leading cause of hospitalization for infants in the United States\(^ {20,21}\) and the associated hospitalization costs are more than $500 million per year.\(^ {22}\) In a nationally representative sample, bronchiolitis hospitalization rates increased 2.4-fold from 1980 to 1996\(^ {20}\) and in a Tennessee Medicaid database there was a 41% increase in bronchiolitis visits at all levels of care (ie, inpatient, emergency department [ED], and outpatient clinic) from 1996 to 2003.\(^ {2}\)

**BRONCHIOLITIS PATHOGENS**

Respiratory syncytial virus (RSV) is the most common pathogen associated with bronchiolitis.\(^ {1,23}\) Although most children are infected with RSV by age 2 years,\(^ {24,25}\) relatively few children (<40%) develop clinically recognized bronchiolitis.\(^ {24,26}\) Among those children who develop bronchiolitis, most have a mild course; approximately 2% to 3% will be hospitalized\(^ {20,27}\) and less than 1% will be admitted to an ICU, intubated, or die.\(^ {28–31}\)

Other viruses that have been linked to bronchiolitis include rhinovirus (RV),\(^ {32,33}\) human metapneumovirus (hMPV),\(^ {34}\) influenza A/B,\(^ {35,36}\) parainfluenza (PIV),\(^ {37}\) and adenovirus.\(^ {38,39}\) Coronaviruses also have been linked to lower respiratory tract disease in children,\(^ {40}\) including the strains NL-63\(^ {41}\) or New Haven\(^ {42}\) and HKU1.\(^ {43–45}\) More recently discovered viruses include human bocavirus\(^ {46–49}\) and the polyomaviruses WU\(^ {50}\) and KI.\(^ {51}\) The clinical relevance of these two polyomaviruses is uncertain.\(^ {52}\) Furthermore, there is conflicting literature about the relevance of bacterial coinfection in children who have viral bronchiolitis, especially those children requiring intensive care.\(^ {53–56}\)

Although myriad infectious causes are associated with bronchiolitis, it remains unclear if the viral cause of a child’s bronchiolitis illness is clinically relevant for either the short- or long-term care of the individual child. For short-term care, knowing the infectious cause identifies children who have influenza who may benefit from oseltamivir; it also helps cohort hospitalized children. Otherwise the current consensus is that knowledge of the viral etiology—among those viruses with easily accessible point-of-care testing (eg, RSV and influenza)—does not affect treatment of the individual patient.\(^ {10}\) As rapid microarray testing becomes less costly and more widely used, however, we are likely to learn much more about the short- and long-term implications of the diverse viruses linked to bronchiolitis. Indeed, these new data could markedly change current understanding and consensus.
EPIDEMIOLOGY OF PATHOGENS AT DIFFERENT LEVELS OF CARE

Several studies have examined the epidemiology of different viruses associated with LRTI in hospitalized children, but there are fewer studies investigating the epidemiology of viruses linked to bronchiolitis in children presenting to the ED or in outpatient clinics. In this section, we present one representative study from the three levels of care (inpatient, ED, outpatient clinic) from different regions of the world.

An inpatient study by Wolf and colleagues compared the clinical features of RSV, hMPV, influenza A, parainfluenza, and adenovirus in 516 Israeli children younger than 5 years of age who were hospitalized with LRTI over a 1-year period. The investigators detected a virus in 57% of the children tested in this single-center study. Children hospitalized with RSV were younger than those hospitalized with hMPV, but the severity of the respiratory illness caused by RSV and hMPV was similar and higher than that of influenza A.

In a multicenter ED-based study of 277 United States children who had physician-diagnosed bronchiolitis, we examined the frequencies of RSV, RV, hMPV, and influenza A/B during one bronchiolitis winter season. We detected a virus in 84% of the samples; RSV was the most common (64%) and RV the second most common (16%).

In a community-based birth cohort sample of Australian children at high risk for atopy (ie, one parent with history of asthma, hay fever, or eczema), Kusel and colleagues examined the frequency of nine different pathogens in these children during their first year. When the children had acute respiratory infections (either upper or lower) the children had nasopharyngeal samples taken. For upper and lower respiratory tract infections in the first year of life, RV was the most frequent cause (48%) and RSV the second most common (11%).

Most data indicate that RSV and RV are the two most common viruses associated with LRTI in early childhood. RSV is detected more frequently from children in the hospital or ED and RV is detected more frequently from children in the outpatient clinic setting.

COINFECTIONS

When considering the cohorting of inpatients, it is important to realize that the aforementioned infectious agents may cause bronchiolitis in isolation or in combination with other infectious agents. Although older studies report coinfections (eg, detection of two or more viruses from the same biologic sample) in 4.4% to 23.7% of children younger than 3 years of age who had respiratory illnesses, recent studies have found 20% to 27% coinfections when testing hospitalized children who had LRTI. There is a lack of clear data, however, about the clinical characteristics of children who have coinfections. Some studies have found no increase in the severity of disease from coinfections as measured by hospital length of stay, clinical symptoms, a severity score, or duration of illness. Other data, however, demonstrate that children infected with multiple pathogens have more severe bronchiolitis as measured by higher hospitalization rates or degree of hypoxia and longer hospital length of stay.

It is likely that the clinical course of coinfections will differ; some combinations of viruses are more or less deleterious than others. One combination that is believed to increase the severity of illness is RSV and hMPV coinfection. As part of a larger study examining severe bronchiolitis, RSV and hMPV were identified in the bronchoalveolar fluid of 70% of 30 intubated infants. In a different study, 72% of 25 intubated children had RSV and hMPV coinfection compared with 10% of 171 children hospitalized on the general wards. Interestingly, hMPV was also found in 5 of 9 patients...
during the 2003 severe acute respiratory syndrome or SARS outbreak in Canada. Recent studies investigating RSV and hMPV suggest that they may have distinctive pathogenesis, elicit unique cytokine profiles, and use different mechanisms to activate human dendritic cells, which play a key role in the adaptive immune response. Moreover, a prospective study by Laham and colleagues measured cytokine levels in Buenos Aires infants presenting with upper or lower respiratory tract illness and discovered that the 22 infants who had hMPV were poor inducers of inflammatory cytokines compared with the 46 infants who had RSV. The authors concluded that the viruses elicit disease by different mechanisms and therefore hMPV may augment RSV disease severity. To date, however, studies not only have not had the sample size to answer definitively if coinfection with hMPV and RSV increases bronchiolitis severity but also have been inadequate to determine the clinical implications of the many other pathogen combinations.

In a cooperative agreement with the National Institutes of Health, our research group, the Emergency Medicine Network (EMNet; www.emnet-usa.org), is currently conducting a prospective, multicenter study that will examine the clinical usefulness of testing for the causes of bronchiolitis in 2250 hospitalized children. Based on the first year of our study, with a sample of 520 hospitalized children, we were able to detect a virus in 93% of the nasopharyngeal samples and found a 27% coinfection rate. In the first year we have found that coinfection was significantly less likely for hospitalized children who had RSV (33%; 95% CI, 28%–38%) as compared with children who had RV (65%; 95% CI, 56%–73%).

WHEEZING AFTER SEVERE BRONCHIOLITIS

In 1959, Wittig and Glaser noted a relationship between bronchiolitis and risk for asthma in 100 children in the United States. Over the past 50 years, several research groups have followed small cohorts of children hospitalized with bronchiolitis for the development of recurrent wheezing. For example, Carlsen and colleagues found that 60% of 51 Norwegian infants hospitalized with bronchiolitis developed recurrent wheezing of childhood (≥3 episodes of bronchial obstruction) by age 2 years compared with 4% of 24 control children. In a retrospective study from Qatar, 31 of 70 (44%) children younger than 12 months hospitalized with RSV bronchiolitis developed recurrent wheezing (≥3 episodes of physician-diagnosed expiratory rhonchi) 2 years after admission, compared with 9 of the 70 controls (12%). Sigurs and colleagues followed a Swedish cohort of 47 infants hospitalized with RSV bronchiolitis and 93 controls up to age 13 years. At a mean age of 3 years, recurrent wheezing was diagnosed in 11 of 47 children (23%) in the RSV group versus 1 of 93 children (1%) in the control group.

Many of the children who have bronchiolitis who develop recurrent wheezing of childhood also develop childhood asthma. Unfortunately, the respiratory morbidity associated with childhood respiratory infections may be longstanding and influence the development and persistence of adult respiratory conditions. In the Swedish cohort, the cumulative prevalence of asthma at age 7 years was 30% in the RSV group versus 3% in the control group and at age 13 years the cumulative prevalence of asthma was 37% in the RSV group versus 5% among controls. In the Tucson Children’s Respiratory Study prospective birth cohort, having an RSV LRTI before age 3 years was an independent risk factor for wheezing up to age 11 years. The association steadily subsides after age 3 years, however, and by age 13 years the association is no longer statistically significant. Unlike the Swedish study, nearly all of the Tucson children who had RSV LRTI were not hospitalized and the respiratory
outcomes of these two populations (ie, inpatient and outpatient) may be quite different. Indeed, based on a Tennessee Medicaid database there is a dose–response relationship between bronchiolitis severity (as defined by inpatient, ED, and outpatient clinic) and the increased odds of early childhood asthma and asthma-specific morbidity.\textsuperscript{96} Despite the generally strong associations, no one has been able to identify reliably the subset of children hospitalized with bronchiolitis at increased risk for developing recurrent wheezing or if most of this large group of children will ultimately develop asthma.\textsuperscript{97} Hampering this pursuit has been the terminology used to describe wheezing in preschool children\textsuperscript{4} and the recent appreciation that asthma is a heterogeneous disease with multiple complex causes.\textsuperscript{8,98,99}

RHINOVIRUS BRONCHIOLITIS

Although RSV is the most common pathogen associated with severe bronchiolitis\textsuperscript{1,23} and has been effectively used to define cohorts of children who have bronchiolitis,\textsuperscript{28,91,92} other pathogens may have a stronger association with recurrent wheezing.\textsuperscript{100–103} The most intriguing virus in studying recurrent wheezing and asthma is RV. Several recent single-center studies have linked RV infection to asthma exacerbations in children and adults,\textsuperscript{104,105} infant wheezing,\textsuperscript{68,106} and infants who have recurrent respiratory symptoms and abnormal lung function.\textsuperscript{107} Recent evidence also links LRTIs with RV-related wheezing in infancy to later development of recurrent wheezing of childhood\textsuperscript{63} and asthma at age 6 years.\textsuperscript{108–110} For example, in the Childhood Origins of ASThma (COAST) birth cohort study, which involves 289 children at high risk for developing asthma, the most significant independent predictor of recurrent wheezing at age 3 years was a moderate to severe RV illness with wheezing during infancy.\textsuperscript{63} Furthermore, a Tennessee study showed that bronchiolitis during RV-predominant months was associated with a 25% increased risk for childhood asthma over bronchiolitis during RSV-predominant months.\textsuperscript{111} Our prospective multicenter data of children younger than 2 years of age presenting to the ED with bronchiolitis found that children who have RV bronchiolitis have similar demographics, medical histories, and ED treatments as older children who have an asthma exacerbation.\textsuperscript{67}

Of particular interest, and with potentially large clinical implications, are the results from one small trial of prednisolone for 3 days versus placebo for children hospitalized with their first or second episode of wheezing due to RV. In this trial, Jartti, Lehtinen, and colleagues\textsuperscript{112} found that children who had RV who received prednisolone had reduced relapses during a 2-month period after the hospitalization and reduced recurrent wheezing at 1 year.\textsuperscript{113} Indeed, children who develop wheezing due to RV seem to have a high likelihood of recurrent wheezing of childhood and eventually later developing asthma.\textsuperscript{110} Further investigation is warranted to clarify the potential value of targeting children who have RV bronchiolitis for the primary prevention of asthma.

Although this review focuses on viruses, we want to remind readers that the specific bacteria colonizing an infant’s hypopharynx also may play an important role in the risk for recurrent wheezing and childhood asthma.\textsuperscript{114} In other words, a child’s long-term outcome probably represents an interaction between the infecting virus, bacterial milieu (colonization or super-infection), and undoubtedly other factors (see Fig. 1).

VITAMIN D AND WHEEZING

Although there are many risk factors for the development of severe bronchiolitis\textsuperscript{2,115} and the development of recurrent wheezing/asthma,\textsuperscript{58,96,116–119} an emerging risk
factor of particular interest to our research group is vitamin D status. Vitamin D3 (cholecalciferol) comes from two sources: exposure to sunlight and dietary intake. The major source of vitamin D for most humans is from exposure of skin to the B fraction of ultraviolet light (UVB). In northern latitudes between November and March there are insufficient UVB rays to produce vitamin D, however. Sunscreen use is recommended to protect against future skin cancer, and this further decreases vitamin D skin production. Unfortunately, lifestyle changes over the past few decades have made vitamin D deficiency increasingly common.

The evidence for the possible link between vitamin D and respiratory disease comes from multiple studies. Two family-based studies demonstrated that gene polymorphisms on the vitamin D receptor were associated with childhood and adult asthma and vitamin D deficiency is correlated with lower pulmonary function in adolescents and adults. Of greater relevance, Camargo and colleagues discovered in a prospective birth cohort in Massachusetts that lower maternal intake of vitamin D during pregnancy is associated with increased risk for recurrent wheezing in the mothers’ young children. These findings were replicated in 5-year-old Scottish children. Camargo and colleagues recently confirmed these novel findings in a separate birth cohort of 922 children from New Zealand (41°–43° S) where low 25-hydroxyvitamin D (25[OH]D) levels in cord blood were associated with increased risk for respiratory infections and childhood wheezing. Moreover, Litonjua and colleagues recently examined the association between serum 25(OH)D levels and risk for an asthma-related ED visit or hospitalization. Among 1022 children who had asthma in the Childhood Asthma Management Program (CAMP), those who had low baseline 25(OH)D levels (<75 nmol/L) were more likely to have a severe asthma exacerbation over a 4-month period (OR 1.50; 95%CI, 1.13–1.98). Finally, Brehm and colleagues recently reported that among 616 children in Costa Rica who had asthma, higher 25(OH)D levels were significantly associated with reduced odds of any hospitalization and reduced use of anti-inflammatory medications.

The pathophysiology of these associations may relate to vitamin D’s role in the activity of the innate immune system. The innate immune system, specifically the activity of cathelicidin, helps prevent infections with bacteria and viruses. In 2006, Liu and colleagues reported in Science a link between Toll-like receptors (TLR), low vitamin D, and the reduced ability to support cathelicidin messenger RNA
induction. Wang and colleagues\textsuperscript{138} also have demonstrated that vitamin D is a direct inducer of the cathelicidin gene. Most recently, Janssen and colleagues determined that single nucleotide polymorphisms in four of the innate immunity genes, including the vitamin D receptor, helped predict susceptibility to RSV bronchiolitis.\textsuperscript{147,148} Taken together, the clinical and mechanistic data support a role for vitamin D as an important factor in the relation between respiratory viruses in bronchiolitis and their link to recurrent wheezing.

SUMMARY

Bronchiolitis is the leading cause of hospitalization for children younger than 1 year of age and these hospitalized children have an increased risk for developing childhood asthma. It remains unclear, however, which children who have severe bronchiolitis (eg, an episode requiring hospitalization) will develop recurrent wheezing or asthma. Two intriguing factors are bronchiolitis due to RV and low levels of vitamin D. Developing a clearer understanding of the complex pathway from bronchiolitis to asthma would help identify the subset of children who have severe bronchiolitis who are at high risk for developing asthma. This understanding would not only help clinicians target follow-up care but also advance bronchiolitis and asthma prevention research by better routing high-risk children into future randomized trials.

REFERENCES

1. Glezen WP, Loda FA, Clyde WA Jr, et al. Epidemiologic patterns of acute lower respiratory disease of children in a pediatric group practice. J Pediatr 1971; 78(3):397–406.
2. Carroll KN, Gebretsadik T, Griffin MR, et al. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics 2008;122(1):58–64.
3. Singh AM, Moore PE, Gern JE, et al. Bronchiolitis to asthma: a review and call for studies of gene-virus interactions in asthma causation. Am J Respir Crit Care Med 2007;175(2):108–19.
4. Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008;32(4):1096–110.
5. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000;161(5):1501–7.
6. Wainwright C, Isles AF, Francis PW. Asthma in children. Med J Aust 1997;167(4):218–23.
7. Yunginger JW, Reed CE, O’Connell EJ, et al. A community-based study of the epidemiology of asthma. Incidence rates, 1964–1983. Am Rev Respir Dis 1992;146(4):888–94.
8. Martinez FD. Gene-environment interactions in asthma: with apologies to William of Ockham. Proc Am Thorac Soc 2007;4(1):26–31, PMCID: 2647610.
9. Yorita KL, Holman RC, Sejvar JJ, et al. Infectious disease hospitalizations among infants in the United States. Pediatrics 2008;121(2):244–52.
10. Diagnosis and management of bronchiolitis. Pediatrics 2006;118(4):1774–93.
11. Hanson IC, Shearer WT. Bronchiolitis. In: McMillan JA, DeAngelis CD, Feigin RD, et al, editors. Oski's pediatrics principles and practice. 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 1214–6.
12. Fleisher GR. Infectious disease emergencies. In: Fleisher GR, Ludwig S, editors. Textbook of pediatric emergency medicine. 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 754–5.

13. Welliver R. Bronchiolitis and infectious asthma. In: Feigin R, Cherry J, Demmler G, et al, editors. Textbook of pediatric infectious diseases. 5th edition. Philadelphia: Saunders; 2004. p. 273–85.

14. Calogero C, Sly PD. Acute viral bronchiolitis: to treat or not to treat—that is the question. J Pediatr 2007;151(3):235–7.

15. Martinon-Torres F, Rodriguez-Nunez A, Martinon-Sanchez JM. Heliox therapy in infants with acute bronchiolitis. Pediatrics 2002;109(1):68–73.

16. Kuzik BA, Al-Qadhi SA, Kent S, et al. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr 2007;151(3):266–70, 70 e1.

17. Corneli HM, Zorc JJ, Majahan P, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 2007;357(4):331–9.

18. Jartti T, Lehtinen P, Vuorinen T, et al. Bronchiolitis: age and previous wheezing episodes are linked to viral etiology and atopic characteristics. Pediatr Infect Dis J 2009;28(4):311–7.

19. Mansbach JM, Espinola JA, Macias CG, et al. Variability in the diagnostic labeling of nonbacterial lower respiratory tract infections: a multicenter study of children who presented to the Emergency Department. Pediatrics 2009;123:e573–81.

20. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 1999;282(15):1440–6.

21. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002;21(7):629–32.

22. Pelletier AJ, Mansbach JM, Camargo CA Jr. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics 2006;116(6):2418–23.

23. Hall CB, Walsh EE, Schnabel KC, et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990;162(6):1283–90.

24. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140(6):543–6.

25. Ukkonen P, Hovi T, von Bonsdorff CH, et al. Age-specific prevalence of complement-fixing antibodies to sixteen viral antigens: a computer analysis of 58,500 patients covering a period of eight years. J Med Virol 1984;13(2):131–48.

26. Levine DA, Platt SL, Dayan PS, et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. Pediatrics 2004;113(6):1728–34.

27. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000;137(6):865–70.

28. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126(2):212–9.

29. Willson DF, Horn SD, Hendley JO, et al. Effect of practice variation on resource utilization in infants hospitalized for viral lower respiratory illness. Pediatrics 2001;108(4):851–5.

30. Holman RC, Shay DK, Curns AT, et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J 2003;22(6):483–90.
31. Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis 2001;183(1):16–22.

32. Papadopoulos NG, Bates PJ, Bardin PG, et al. Rhinoviruses infect the lower airways. J Infect Dis 2000;181(6):1875–84.

33. Korppi M, Kotaniemi-Syrjanen A, Waris M, et al. Rhinovirus-associated wheezing in infancy: comparison with respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J 2004;23(11):995–9.

34. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7(6):719–24.

35. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292(11):1333–40.

36. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342(4):225–31.

37. Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004;113(6):1758–64.

38. Rocholl C, Gerber K, Daly J, et al. Adenoviral infections in children: the impact of rapid diagnosis. Pediatrics 2004;113(1 Pt 1):e51–6.

39. Edwards KM, Thompson J, Paolini J, et al. Adenovirus infections in young children. Pediatrics 1985;76(3):420–4.

40. McIntosh K, Kapikian AZ, Turner HC, et al. Seroepidemiologic studies of coronavirus infection in adults and children. Am J Epidemiol 1970;91(6):585–92.

41. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004;10(4):368–73.

42. Esper F, Weibel C, Ferguson D, et al. Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J Infect Dis 2005;191(4):492–8.

43. Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005;79(2):884–95.

44. Lau SK, Woo PC, Yip CC, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol 2006;44(6):2063–71.

45. Esper F, Weibel C, Ferguson D, et al. Coronavirus HKU1 infection in the United States. Emerg Infect Dis 2006;12(5):775–9.

46. Allander T, Tammi MT, Eriksson M, et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 2005;102(36):12891–6.

47. Foulongne V, Rodiere M, Segondy M. Human bocavirus in children. Emerg Infect Dis 2006;12(5):862–3.

48. Bastien N, Brandt K, Dust K, et al. Human bocavirus infection, Canada. Emerg Infect Dis 2006;12(5):848–50.

49. Ma X, Endo R, Ishiguro N, et al. Detection of human bocavirus in Japanese children with lower respiratory tract infections. J Clin Microbiol 2006;44(3):1132–4.

50. Gaynor AM, Nissen MD, Whiley DM, et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog 2007;3(5):e64.

51. Allander T, Andreasson K, Gupta S, et al. Identification of a third human polyomavirus. J Virol 2007;81(8):4130–6, PMCID: 1866148.
52. Wattier RL, Vazquez M, Weibel C, et al. Role of human polyomaviruses in respiratory tract disease in young children. Emerg Infect Dis 2008;14(11):1766–8, PMCID: 2630739.

53. Duttweiler L, Nadal D, Frey B. Pulmonary and systemic bacterial co-infections in severe RSV bronchiolitis. Arch Dis Child 2004;89(12):1155–7, PMCID: 1719766.

54. Hall CB, Powell KR, Schnabel KC, et al. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. J Pediatr 1988;113(2):266–71.

55. Randolph AG, Reder L, Englund JA. Risk of bacterial infection in previously healthy respiratory syncytial virus-infected young children admitted to the intensive care unit. Pediatr Infect Dis J 2004;23(1 Suppl):S11–8.

56. Henrickson KJ, Kehl KS, Werno AM, et al. Single versus dual respiratory virus infections in hospitalized infants: impact on clinical course of disease and interferon-gamma response. Pediatr Infect Dis J 2005;24(7):611–6.

57. Aberle JH, Aberle SW, Pracher E, et al. Single versus dual respiratory virus infections in hospitalized infants: impact on clinical course of disease and interferon-gamma response. Pediatr Infect Dis J 2005;24(7):605–10.

58. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004;350(5):443–50.

59. Legg JP, Warner JA, Johnston SL, et al. Frequency of detection of picornaviruses and seven other respiratory pathogens in infants. Pediatr Infect Dis J 2005;24(7):611–6.

60. Mansbach JM, McAdam AJ, Clark S, et al. Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort study. Pediatr Infect Dis J 2006;25(4):320–4.

61. Mansbach JM, McAdam AJ, Clark S, et al. Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort study. Pediatr Infect Dis J 2006;25(4):320–4.
Respiratory Viruses in Bronchiolitis

69. Jacobs JW, Peacock DB, Corner BD, et al. Respiratory syncytial and other viruses associated with respiratory disease in infants. Lancet 1971;1(7705):871–6.

70. Meissner HC, Murray SA, Kiernan MA, et al. A simultaneous outbreak of respiratory syncytial virus and parainfluenza virus type 3 in a newborn nursery. J Pediatr 1984;104(5):680–4.

71. Mufson MA, Krause HE, Mocega HE, et al. Viruses, Mycoplasma pneumoniae and bacteria associated with lower respiratory tract disease among infants. Am J Epidemiol 1970;91(2):192–202.

72. Ray CG, Minnich LL, Holberg CJ, et al. Respiratory syncytial virus-associated lower respiratory illnesses: possible influence of other agents. The Group Health Medical Associates. Pediatr Infect Dis J 1993;12(1):15–9.

73. Waner JL, Whitehurst NJ, Jonas S, et al. Isolation of viruses from specimens submitted for direct immunofluorescence test for respiratory syncytial virus. J Pediatr 1986;108(2):249–50.

74. Downham MA, Gardner PS, McQuillin J, et al. Role of respiratory viruses in childhood mortality. Br Med J 1975;1(5952):235–9.

75. Portnoy B, Eckert HL, Hanes B, et al. Multiple respiratory virus infections in hospitalized children. Am J Epidemiol 1965;82(3):262–72.

76. Subbarao EK, Griffis J, Waner JL. Detection of multiple viral agents in nasopharyngeal specimens yielding respiratory syncytial virus (RSV). An assessment of diagnostic strategy and clinical significance. Diagn Microbiol Infect Dis 1989;12(4):327–32.

77. Drews AL, Atmar RL, Glezen WP, et al. Dual respiratory virus infections. Clin Infect Dis 1997;25(6):1421–9.

78. Foulounge V, Guyon G, Rodiere M, et al. Human metapneumovirus infection in young children hospitalized with respiratory tract disease. Pediatr Infect Dis J 2006;25(4):354–9.

79. Greensill J, McNamara PS, Dove W, et al. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg Infect Dis 2003;9(3):372–5.

80. Semple MG, Cowell A, Dove W, et al. Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis. J Infect Dis 2005;191(3):382–6.

81. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348(20):1995–2005.

82. Guerrero-Plata A, Casola A, Garofalo RP. Human metapneumovirus induces a profile of lung cytokines distinct from that of respiratory syncytial virus. J Virol 2005;79(23):14992–7.

83. Alvarez R, Tripp RA. The immune response to human metapneumovirus is associated with aberrant immunity and impaired virus clearance in BALB/c mice. J Virol 2005;79(10):5971–8.

84. Douville RN, Bastien N, Li Y, et al. Human metapneumovirus elicits weak IFN-γ memory Responses compared with respiratory syncytial virus. J Immunol 2006;176(10):5848–55.

85. Mahalingam S, Schwarze J, Zaid A, et al. Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial infections? Microbes Infect 2006;8(1):285–93.

86. Guerrero-Plata A, Casola A, Suarez G, et al. Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus. Am J Respir Cell Mol Biol 2006;34(3):320–9.

87. Laham FR, Israele V, Casellas JM, et al. Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other
common respiratory viruses of infancy. J Infect Dis 2004;189(11):2047–56, (Print).
88. Piedra P, Mansbach JM, Jewell A, et al. Prospective multicenter study of the etiology of bronchiolitis admissions 2007–2008. Baltimore (MD): Pediatric Academic Societies; 2009.
89. Wittig HJ, Glaser J. The relationship between bronchiolitis and childhood asthma; a follow-up study of 100 cases of bronchiolitis. J Allergy 1959;30(1):19–23.
90. Carlsen KH, Larsen S, Bjerve O, et al. Acute bronchiolitis: predisposing factors and characterization of infants at risk. Pediatr Pulmonol 1987;3(3):153–60.
91. Osundwa VM, Dawod ST, Ehlayel M. Recurrent wheezing in children with respiratory syncytial virus (RSV) bronchiolitis in Qatar. Eur J Pediatr 1993;152(12): 1001–3.
92. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995;95(4):500–5.
93. Dharmage SC, Erbas B, Jarvis D, et al. Do childhood respiratory infections continue to influence adult respiratory morbidity? Eur Respir J 2009;33(2): 237–44.
94. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171(2):137–41.
95. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354(9178):541–5.
96. Carroll KN, Wu P, Gebretsadik T, et al. The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. J Allergy Clin Immunol 2009;123(5):1055–61.
97. Frey U, Von Mutius E. The challenge of managing wheezing in infants. N Engl J Med 2009;360(20):2130–3.
98. Borish L, Culp JA. Asthma: a syndrome composed of heterogeneous diseases. Ann Allergy Asthma Immunol 2008;101(1):1–8 [quiz: 11, 50].
99. Reed CE. The natural history of asthma. J Allergy Clin Immunol 2006;118(3): 543–8 [quiz: 9–50].
100. Valkonen H, Waris M, Ruohola A, et al. Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up. Allergy 2009 [epub ahead of print].
101. Reijonen TM, Korppi M. One-year follow-up of young children hospitalized for wheezing: the influence of early anti-inflammatory therapy and risk factors for subsequent wheezing and asthma. Pediatr Pulmonol 1998;26(2):113–9.
102. Reijonen TM, Kotaniemi-Syrjanen A, Korhonen K, et al. Predictors of asthma three years after hospital admission for wheezing in infancy. Pediatrics 2000; 106(6):1406–12.
103. Lee KK, Hegele RG, Manfreda J, et al. Relationship of early childhood viral exposures to respiratory symptoms, onset of possible asthma and atopy in high risk children: the Canadian asthma primary prevention study. Pediatr Pulmonol 2007;42(3):290–7.
104. Rawlinson WD, Waliuzzaman Z, Carter IW, et al. Asthma exacerbations in children associated with rhinovirus but not human metapneumovirus infection. J Infect Dis 2003;187(8):1314–8.
105. Venarske DL, Busse WW, Griffin MR, et al. The relationship of rhinovirus-associated asthma hospitalizations with inhaled corticosteroids and smoking. J Infect Dis 2006;193(11):1536–43.
106. Rakes GP, Arruda E, Ingram JM, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med 1999;159(3):785–90.

107. Malmstrom K, Pitkaranta A, Carpen O, et al. Human rhinovirus in bronchial epithelium of infants with recurrent respiratory symptoms. J Allergy Clin Immunol 2006;118(3):591–6.

108. Roberg KA, Sullivan-Dillie KT, Evans MD, et al. Wheezing severe rhinovirus illnesses during infancy predict childhood asthma at age 6 years. J Allergy Clin Immunol 2007;119(1):619 [abstract].

109. Kotaniemi-Syrjanen A, Vainionpaa R, Reijonen TM, et al. Rhinovirus-induced wheezing in infancy—the first sign of childhood asthma? J Allergy Clin Immunol 2003;111(1):66–71.

110. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008;178(7):667–72.

111. Carroll KN, Wu P, Gebretsadik T, et al. Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma. J Allergy Clin Immunol 2009;123(4):964–6.

112. Jartti T, Lehtinen P, Vanto T, et al. Evaluation of the efficacy of prednisolone in early wheezing induced by rhinovirus or respiratory syncytial virus. Pediatr Infect Dis J 2006;25(6):482–8.

113. Lehtinen P, Ruohola A, Vanto T, et al. Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema. J Allergy Clin Immunol 2007;119(3):570–5.

114. Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 2007;357(15):1487–95.

115. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143(5 Suppl):S118–26.

116. Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995;332(3):133–8.

117. Guilbert TW, Morgan WJ, Zeiger RS, et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol 2004;114(6):1282–7.

118. Wu P, Dupont WD, Griffin MR, et al. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am J Respir Crit Care Med 2008;178(11):1123–9.

119. Matricardi PM, Illi S, Gruber C, et al. Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence. Eur Respir J 2008;32(3):585–92.

120. Mansbach JM, Camargo CA Jr. Bronchiolitis: lingering questions about its definition and the potential role of vitamin D. Pediatrics 2008;122(1):177–9.

121. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988;67(2):373–8.

122. Marks R, Jolley D, Lectsas S, et al. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med J Aust 1990;152(2):62–6.

123. Autier P, Dore JF. Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group.
European Organisation for Research and Treatment of Cancer. Int J Cancer 1998;77(4):533–7.

124. Gilchrest BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999;340(17):1341–8.

125. Fuller KE, Casparian JM, Vitamin D. Balancing cutaneous and systemic considerations. South Med J 2001;94(1):58–64.

126. Lee JM, Smith JR, Philipp BL, et al. Vitamin D deficiency in a healthy group of mothers and newborn infants. Clin Pediatr (Phila) 2007;46(1):42–4.

127. Ziegler EE, Hollis BW, Nelson SE, et al. Vitamin D deficiency in breastfed infants in Iowa. Pediatrics 2006;118(2):603–10.

128. Poon AH, Laprise C, Lemire M, et al. Association of vitamin D receptor genetic variants with susceptibility to asthma and atopy. Am J Respir Crit Care Med 2004;170(9):967–73.

129. Raby BA, Lazarus R, Silverman EK, et al. Association of vitamin D receptor gene polymorphisms with childhood and adult asthma. Am J Respir Crit Care Med 2004;170(10):1057–65.

130. Burns J, Dockery D, Speizer FE. Low levels of dietary vitamin D intake and pulmonary function in adolescents. Proc Am Thorac Soc 2006;3:526 [abstract].

131. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest 2005;128(6):3792–8.

132. Camargo CA Jr, Rifas-Shiman SL, Litonjua AA, et al. Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age. Am J Clin Nutr 2007;85(3):788–95.

133. Devereux G, Litonjua AA, Turner SW, et al. Maternal vitamin D intake during pregnancy and early childhood wheezing. Am J Clin Nutr 2007;85(3):853–9.

134. Camargo CA Jr, Ingham T, Wickens K, et al. Cord blood 25-hydroxyvitamin D levels and risk of childhood wheeze in New Zealand. Am J Respir Crit Care Med. 2008;177(Suppl):A993 [abstract].

135. Litonjua AA, Hollis BW, Scheumann B, et al. Low serum vitamin D levels are associated with greater risks for severe exacerbations in childhood asthmatics. Am J Respir Crit Care Med 2008;177(suppl):A993 [abstract].

136. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000;343(15):1054–63.

137. Brehm JM, Celedon JC, Soto-Quiros ME, et al. Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med 2009;179(9):765–71.

138. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173(5):2909–12.

139. Schaub et, Dorschner RA, Coda AB, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 2007;117(3):803–11.

140. Martineau AR, Wilkinson KA, Newton SM, et al. IFN-γ- and TNF-independent vitamin D-inducible human suppression of Mycobacteria: the role of cathelicidin LL-37. J Immunol 2007;178(11):7190–8.

141. Mansbach & Camargo
143. Zhang L, Yu W, He T, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002;298(5595):995–1000.

144. Leikina E, Delanoe-Ayari H, Melikov K, et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 2005;6(10):995–1001.

145. Bastian A, Schafer H. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept 2001;101(1–3):157–61.

146. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311(5768):1770–3.

147. Janssen R, Bont L, Siezen CL, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis 2007;196(6):826–34.

148. Roth DE, Jones AB, Prosser C, et al. Vitamin D receptor polymorphisms and the risk of acute lower respiratory tract infection in early childhood. J Infect Dis 2008;197:676–80.